Absci is trading 6.67% up now at $10.47, but the catalyst remains unclear.
- No new company-specific announcement dated September 22, 2026, was identified; the latest investor-relations item was its September 1 conference announcement.
- Broader support is limited: the Nasdaq Composite is up 0.40%, below the stated 0.5% threshold.
- Recent investor-conference activity and prior positive clinical data provide additional context.